Hybio Pharmaceutical
Shenzhen · Founded 1998
About Hybio Pharmaceutical
Shenzhen Hybio Pharmaceutical Co., Ltd. (翰宇药业) is a high-tech enterprise which is engaged in research, development, production, and sales of polypeptide drugs. On the basis of strict production management and quality control according to the GMP strictly, it breaks through the bottle-neck of the polypeptide drugs' large-scale production technology by means of introduction digestion, independent innovation, and any other patterns. Shenzhen Hybio Pharmaceutical has successively applied for 38 patents, with 5 patents for invention, 7 national new drug certificates, 5 new drug clinical trial permissions, and 45 drug registration letters. The drugs are mainly used to treat diseases such as digestive diseases, cardiovascular and cerebrovascular diseases, diabetes, infectious diseases, tumors, senile diseases, and more.
Company Facts
- Founded: 1998
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $500K – $1M
- Total funding: $13.9M
- Funding stage: IPO
- Last round: Series B (Mar 2009)
- Ticker: szse:300199
- Website: hybio.com.cn
- Phone: 0755-26588000 26588111
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/hybio-pharmaceutical-3214462 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.